468 related articles for article (PubMed ID: 17571739)
1. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
2. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
3. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
5. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H
Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
8. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
[TBL] [Abstract][Full Text] [Related]
9. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Kantarjian H; Sawyers C; Hochhaus A; Guilhot F; Schiffer C; Gambacorti-Passerini C; Niederwieser D; Resta D; Capdeville R; Zoellner U; Talpaz M; Druker B; Goldman J; O'Brien SG; Russell N; Fischer T; Ottmann O; Cony-Makhoul P; Facon T; Stone R; Miller C; Tallman M; Brown R; Schuster M; Loughran T; Gratwohl A; Mandelli F; Saglio G; Lazzarino M; Russo D; Baccarani M; Morra E;
N Engl J Med; 2002 Feb; 346(9):645-52. PubMed ID: 11870241
[TBL] [Abstract][Full Text] [Related]
10. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Fischer T; Reifenrath C; Hess GR; Corsetti MT; Kreil S; Beck J; Meinhardt P; Beltrami G; Schuch B; Gschaidmeier H; Hehlmann R; Hochhaus A; Carella A; Huber C
Leukemia; 2002 Jul; 16(7):1220-8. PubMed ID: 12094246
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Nimmanapalli R; Bhalla K
Oncogene; 2002 Dec; 21(56):8584-90. PubMed ID: 12476305
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction inhibitors (STI571): molecularly targeted therapy.
Corujo Y; Cáceres W
P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].
Mayer J
Vnitr Lek; 2002 Jan; 48(1):45-9. PubMed ID: 11852587
[TBL] [Abstract][Full Text] [Related]
17. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
18. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M
Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603
[TBL] [Abstract][Full Text] [Related]
19. [Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment].
Casado LF; Picó M; Gómez C; Ferro MT; Fernández-Rañada JM; Steegmann JL
Med Clin (Barc); 1997 Sep; 109(7):251-5. PubMed ID: 9333689
[TBL] [Abstract][Full Text] [Related]
20. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Mattiuzzi GN; Cortes JE; Talpaz M; Reuben J; Rios MB; Shan J; Kontoyiannis D; Giles FJ; Raad I; Verstovsek S; Ferrajoli A; Kantarjian HM
Clin Cancer Res; 2003 Mar; 9(3):976-80. PubMed ID: 12631595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]